BlueCross/BlueShield of Oregon introduces new generics program
PORTLAND, Ore. Regence BlueCross BlueShield of Oregon has introduced a new program called Generics First Antidepressant Program, to help battle rising healthcare costs.
The program encourages the use of high-quality antidepressant generic medications. Since the company believes generics can meet the needs of most patients, brand-name drugs will require a prior authorization beginning in September. This though, does not necessarily mean that people already on brand-name medications will need a prior authorization.
Prices could result as follows, a 30-day supply of a generic could be $30 compared to a brand-name drug, which could cost $83. “These generics are a good value for members and are available without prior authorization,” said David Clark, vice president of Medical Services and Pharmacy for Regence.
Teva receives final FDA approval for generic Famvir, but will delay marketing until patent hearing
JERUSALEM Teva Pharmaceuticals has been granted final approval on its application to market famciclovir, the generic version of Novartis’ Famvir in the 125, 250 and 500mgs.
Now with the approval from the Food and Drug Administration, Teva is also awarded a 180-day period of market exclusivity. But the company will hold off marketing the item until at least Sept. 5, 2007.
On that day, a hearing will be held involving a patent infringement suit brought against Teva regarding the famciclovir. The hearing is scheduled to meet at the U.S. District Court for the District of New Jersey regarding Novartis’ motion for a preliminary injunction. Therefore, both parties have agreed to not launch a generic version of Famvir until after the hearing.
Forest, Daiichi Sankyo sign agreement for Azor
NEW YORK Forest Laboratories and Daiichi Sankyo have signed a co-promotional agreement for Daiichi Sankyo’s new antihypertension drug Azor. Azor is a combination of the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil.
Under the agreement, Forest will pay Daiichi Sankyo an upfront payment of $20 million and will receive a payment based upon product sales. The agreement is for three years, after which, Daiichi Sankyo will make residual payments to Forest.
The drug is still under review by the Food and Drug Administration with a decision expected by late September. Hypertension affects roughly 72 million people in the U.S., with about 65 percent of those diagnosed having trouble keeping it under control.